JATT II Acquisition To Merge With Talawar Therapeutics; Combined Company Expects To Receive $285M In PIPE Financing Upon Closing
Oversubscribed $225 million concurrent private investment in public equity ("PIPE") with available cash to the combined company at closing anticipated to fund TALA-125 through a Phase 2b proof-of-concept study data readout in the second half of 2028 Talawar, the first company formed to develop and commercialize assets